We have identified and characterized specific receptors for tetradecapeptide somatostatin (SRIF; somatotropin release-inhibiting factor) in rat brain using 
receptor density to endogenous somatostatin is high in the cortex, thalamus, and striatum, low in the hypothalamus, and extremely low in the brain stem and cerebellum. Thus, SRIF receptors in the brain appear to be a distinct, new class of receptors with a regional distribution different from that ofendogenous somatostatin.
The tetradecapeptide somatostatin (SRIF; somatotropin release-inhibiting factor) originally discovered as a growth hormone release-inhibiting factor in extracts of sheep hypothalami (1) has since been shown to be distributed throughout the extrahypothalamic brain and in peripheral tissues and to exert a wide spectrum of biological actions (24) . Although the precise function of somatostatin in the central nervous system is unknown, the extensive distribution of somatostatin-containing neurons in the brain (5) , its synaptosomal localization (6) , the effects of microiontophoretically applied SRIF on the spontaneous electrical activity of neurons (7) , and the behavioral effects (8) of intracisternally injected SRIF (8) suggest that the peptide may act as a neurotransmitter or neuromodulator (7, 9) . There is good evidence to suggest that the action of SRIF on growth hormone secretion is mediated through binding to specific receptors which have been demonstrated in rat pituitary tumor cells in culture (10) and in bovine pituitary plasma membranes (11) . Similar binding of SRIF to subcellular components of neural tissue has not been reported. Therefore, the present study was designed to identify and characterize specific receptors for SRIF in rat brain synaptosomal membrane fractions that have been shown to possess specific binding sites for other neuropeptides (12) (13) (14) (15) .
MATERLALS AND METHODS Synthetic cyclic SRIF was obtained from Ayerst Laboratories (Montreal, Canada). Tyrosinated analogs of SRIF, thyrotropinreleasing hormone (TRH; thyroliberin), luteinizing hormonereleasing hormone (LHRH; luliberin), substance P, neurotensin, and bombesin were purchased from Bachem Fine Chemicals (Torrance, CA). Other analogs of SRIF were provided by D. Coy and C. Meyers (New Orleans, LA) and J. Rivier (La Jolla, CA). Synthetic 13H-endorphin was obtained from N. Ling (La Jolla, CA), and [Met]enkephalin was from G. Tregear (Melbourne, Australia). Vasoactive intestinal polypeptide (VIP) was a gift from S. I. Said (Dallas, TX). All other chemicals used were of analytical grade.
Preparation of Brain Membranes. Adult male SpragueDawley rats (150-200 g) were killed by decapitation. The cerebral cortex was dissected and homogenized (10%, wt/vol) in 0.32 M sucrose/20 mM Tris-HCl, pH 7.5, with a Dounce homogenizer, and membrane fractions were prepared by a modification of the method of Cotman and Matthews (16) . The homogenate was centrifuged at 1000 X g for 5 min to remove the nuclear debris (fraction P1). The supernatant obtained was centrifuged at 10,000 x g for 45 min. The resulting pellet containing the crude mitochondrial fraction (P2) was resuspended in 0.32 M sucrose, applied to the top of a discontinuous Ficoll (Pharmacia, Uppsala, Sweden) gradient (8-20%) (1981) 3931 been developed for this purpose (19) and have been shown to possess similar biological activities to the native peptide (19, 20 Table 2 . Fraction P5 exhibited the highest specific and lowest nonspecific binding (9.67% and 4.12%, respectively). Morphologically this subfraction was enriched in synaptosomes (Fig. 1) . Less than 0.5% specific binding was observed in fraction P6. Both these fractions contained high concentrations of endogenous somatostatin, 9.7 and 11.0 ng/ mg of protein, respectively, which could be released by hypoosmotic lysis of the synaptosomes ( Table 2) . Removal of the endogenous somatostatin in this manner resulted in a 7-fold increase in the specific binding of ['2I-Tyr"]SRIF to the membranes in P5, whereas no increase was seen in fraction P6. Fraction P7, which consists mainly of myelin (16) (Fig. 2A) .
Nonspecific binding in the presence of 10 ,AM SRIF reached a maximal level by 20 min and remained constant thereafter. When specific binding under these conditions was plotted semilogarithmically, the linear result (Fig. 2B) suggested pseudo- (25) . The half-time for approach to equilibrium binding was 9 min, which corresponds to a pseudo-firstorder rate constant (kobs) of0.077 min1. To test the reversibility ofthe binding of ['25I-Tyr11]SRIF to the membrane fraction P5, the receptor-bound radioligand at equilibrium was removed from the free radioligand and resuspended in the incubation medium with and without added unlabeled SRIF (0.1 MM), and the time course of dissociation was followed at the same temperature. The rates ofdissociation under these conditions were identical, the half-time for dissociation being 26 min, which corresponds to a rate constant koff = 0.027 mind.
When SRIF was added to the incubation medium, the specific binding of [12I-Tyr"]SRIF was inhibited in a dose-dependent manner over a concentration range of0.1 nM to 1 ,.M (Fig.  3) . Fig. 3 Inset shows the Scatchard analysis (24) DISCUSSION We have identified and characterized receptors for SRIF in a subfraction of synaptosomal membranes isolated from rat cerebral cortex that interact with SRIF in a specific, saturable, and reversible manner. Synaptosomes have been shown to sediment in a broad band in continuous gradients of sucrose and Ficoll and appear to be heterogenous (28, 29) . They also have been subfractionated in discontinuous gradients (30) . The two subcellular fractions P5 and P6 identified in the present study appear to be enriched in synaptosomes as shown morphologically for P5 ( Fig. 1) and as reported for the fraction corresponding to P6 (16) . Furthermore, both fractions contained a high concentration of endogenous somatostatin, which decreased substantially after hypoosmotic rupture of the synaptosomes. Thus, our finding of a marked difference in SRIF binding between the two fractions provides further evidence for the heterogeneity of synaptosomes. The high density of receptor sites in synaptosomes suggests that SRIF may function as a neurotransmitter. The subcellular component in the heavier synaptosomal fraction P5 that contains specific receptors for SRIF remains to be identified.
['25I-Tyr"]SRIF was found to be the most suitable radioligand for studying receptor binding. In the two previous reports of SRIF receptors in the pituitary, ['25I-Tyr']SRIF was used as the radioligand (10, 11) . This radioligand was found to undergo up to 20% degradation during incubation with pituitary tumor cells (10) . In the present study, up to 60% degradation of [125I-
Tyr']SRIF was observed during incubation with synaptosomal membrane fraction P5. The high nonspecific binding of ['sITyr']SRIF encountered in the present investigation (>14%) and that reported for bovine pituitary plasma membrane (18%) (11) could be due to binding of damaged fragments of the ra- (32) . In GH4C1 cells, a clonal strain of pituitary tumor cells, TRH has been reported to alter, the specific binding of SRIF to its receptors (33) . In the present study, neither opiates nor TRH or other neuropeptides appeared to influence the binding of SRIF to brain membranes, suggesting that SRIF receptors are distinct from, those of other peptides.
The ability of biologically active analogs to inhibit the specific binding of ['"I-Tyr"]SRIF suggests that the action -of SRIF is probably mediated through binding to its receptors. Additional evidence for this comes from the observation that some biologically inactive analogs tested were significantly less effective in inhibiting radioligand binding. The distribution of SRIF receptors in the rat brain differs from that of opiate (12) , VIP (13), bombesin (14) , carnosine (34), f3adrenergic (35) , and muscarinic/cholinergic (36) receptors. Furthermore, the regional distribution of endogenous somatostatin and its receptors in the brain is not parallel. Maximum receptor density occurs in the cortex, whereas the concentration ofendogenous somatostatin is highest in the hypothalamus. The ratio of receptor concentration to endogenous somatostatin is high in the cortex, thalamus, and striatum, low in the hypothalamus, and extremely low in the brainstem and cerebellum. One possible explanation for the dissociation between endogenous somatostatin and receptor density in the hypothalamus is the predominant localization of hypothalamic somatostatin in neurosecretory neurons which terminate on the capillaries of the portal vessels (37) . However, interaction between SRIF and other peptigeric neurons (e.g., TRH) (38) at an axo-axonic level in the median eminence and somatostatin-containing terminals shown in various hypothalamic nuclei (5) may account for the intermediate concentration of SRIF receptors found in the hypothalamus. The low ratio of receptors to endogenous somatostatin in the brain stem could be due to an upward projection offibers of somatostatin-containing neurons with cell bodies located in the pons and medulla.
